Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Westerweel, P.E."'
Autor:
Schropp, L., Cats, R.B., de Kleijn, R.J.C.M.F., Black, S., Garcia, D., Meijer, K., Nijziel, M.R., Klappe, E.M., Geroulakos, G., van Ommen, C.H., van Rijn, M.J.E., Freischlag, J., Kruip, M.J.H.A., Huisman, M.V., Coppens, M., Teijink, J.A.W., Kakkos, S.K., Le Gal, G., Westerweel, P.E., Avila, M.L., Kreuziger, L. Baumann, Cate-Hoek, A.J. Ten, Lee, A.Y.Y., Koelemay, M.J., Srivastava, A., Hovens, M.M.C., Ünlü, Ç., Klok, F.A., Douketis, J., Stansby, G., Illig, K.A., Thompson, R.W., Bax, W.A., Poli, D., Kahn, S.R., van Hattum, E.S., Middeldorp, S., Nijkeuter, M., Westerink, J., Petri, B.J., de Borst, G.J., Schropp, Ludo, Cats, Roos B., de Kleijn, Robert J.C.M.F., van Hattum, Eline S., Middeldorp, Saskia, Nijkeuter, Mathilde, Westerink, Jan, Petri, Bart-Jeroen, de Borst, Gert J.
Publikováno v:
In Research and Practice in Thrombosis and Haemostasis January 2023 7(1)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jong, C.M.M. de, Blondon, M., Ay, C., Buchmuller, A., Beyer-Westendorf, J., Biechele, J., Bertoletti, L., Colombo, G., Donadini, M.P., Hendriks, S.V., Jara-Palomares, L., Nopp, S., Ruiz-Artacho, P., Stephan, P., Tromeur, C., Vanassche, T., Westerweel, P.E., Klok, F.A., TEAM VTE Investigators
Publikováno v:
Blood, 140(16), 1764-1773. AMER SOC HEMATOLOGY
Preliminary data and clinical experience have suggested an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid data are lacking. The TEAM-VTE study was an international multicenter pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c89b44ac208db214981168c16ee77d4
https://hdl.handle.net/1887/3566939
https://hdl.handle.net/1887/3566939
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Smit, J.M., Krijthe, J.H., Tintu, A.N., Endeman, H., Ludikhuize, J., Genderen, M.E. van, Hassan, S., Moussaoui, R. el, Westerweel, P.E., Goekoop, R.J., Waverijn, G., Verheijen, T., Hollander, J.G. den, Boer, M.G.J. de, Gommers, D.A.M.P.J., Vlies, R. van der, Schellings, M., Carels, R.A., Nieuwkoop, C. van, Arbous, S.M., Bommel, J. van, Knevel, R., Rijke, Y.B. de, Reinders, M.J.T.
Publikováno v:
Intensive Care Medicine Experimental, 10(1):38. Springer Open
Intensive Care Medicine Experimental, 10(1). SPRINGER
Intensive Care Medicine Experimental, 10(1)
Intensive Care Medicine Experimental, 10(1). SPRINGER
Intensive Care Medicine Experimental, 10(1)
Background Timely identification of deteriorating COVID-19 patients is needed to guide changes in clinical management and admission to intensive care units (ICUs). There is significant concern that widely used Early warning scores (EWSs) underestimat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f715f5e014ff1c59a5e97ae1f324ba
http://resolver.tudelft.nl/uuid:8ff92af8-b412-4f21-b800-0a180a630144
http://resolver.tudelft.nl/uuid:8ff92af8-b412-4f21-b800-0a180a630144
Autor:
Lowenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B.J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L.W., Jongen-Lavrencic, M., Kooy, M.V., Vekemans, M.C., Velden, W.J.F.M. van der, Beverloo, B., Michaux, L., Graux, C., Deeren, D., Weerdt, O. de, Esser, J.W.J. van, Bargetzi, M., Klein, S.K., Gadisseur, A., Westerweel, P.E., Veelken, H., Gregor, M., Silzle, T., Lammeren-Venema, D. van, Moors, I., Breems, D.A., Hoogendoorn, M., Legdeur, M.C.J.C., Fischer, T., Kuball, J., Cornelissen, J., Porkka, K., Juliusson, G., Meyer, P., Hoglund, M., Gjertsen, B.T., Janssen, J.J.W.M., Huls, G., Passweg, J., Cloos, J., Valk, P.J.M., Elssen, C.H.M.J. van, Manz, M.G., Floisand, Y., Ossenkoppele, G.J., Dutch-Belgian Hemato-Oncology Coop, Swiss Grp Clinical Canc Res SAKK
Publikováno v:
Blood Adv
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121
Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly
Autor:
Schmidtmann, I. (Irene), Ageno, W. (Walter), Bauersachs, R.M. (Rupert M.), Becattini, C. (Cecilia), Bernardi, E. (Enrico), Beyer-Westendorf, J. (Jan), Bonacchini, L. (Luca), Brachmann, J. (Johannes), Christ, M. (Michael), Czihal, M. (Michael), Duerschmied, D. (Daniel), Empen, K. (Klaus), Espinola-Klein, C. (Christine), Ficker, J.H. (Joachim H.), Fonseca, C. (Candida), Genth-Zotz, S. (Sabine), Jiménez, D. (David), Harjola, V.P. (Veli-Pekka), Held, M. (Matthias), Iogna-Prat, L. (Lorenzo), Lange, T.J. (Tobias J.), Manolis, A. (Athanasios), Meyer, A. (Andreas), Mustonen, P. (Pirjo), Rauch-Kroehnert, U. (Ursula), Ruiz-Artacho, P. (Pedro), Schellong, S. (Sebastian), Schwaiblmair, M. (Martin), Stahrenberg, R. (Raoul), Westerweel, P.E. (Peter), Wild, P.S. (Philipp S.), Konstantinides, S.V. (Stavros V.), Lankeit, M. (Mareike)
Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1111::4c231c894297b0ab7c7166a2e72471d6
https://hdl.handle.net/10171/66343
https://hdl.handle.net/10171/66343
Autor:
Janssen, J.J.M., Boekhorst, P.A.W., Posthuma, E.F., Klein, S.K., Hoogendoorn, M., Waal, T.T. de, Falkenburg, J.H., Biemond, B.J., Reijden, B.A. van der, Bos, G.M., Petersen, E.J., Blijlevens, N.M., Smit, W.M., Verhoef, G.E., Vellenga, E., Thielen, N., Cornelissen, J.J.L.M, Ossenkoppele, G.J., Westerweel, P.E.
Publikováno v:
Nederlands Tijdschrift voor Hematologie, 15, pp. 218-28
Nederlands Tijdschrift voor Hematologie, 15, 218-28
Nederlands Tijdschrift voor Hematologie, 15, 218-28
Item does not contain fulltext